http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:31:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Cogent+%28COGT%29+Reiterated+at+Buy+by+Stifel+After+ASCO+Presentation+on+Bezuclastinib+/26579256.html <p>Stifel analyst Laura Prendergast reiterated a Buy rating and $45.00 price target on Cogent (NASDAQ: COGT).</p><p>The analyst commented, " At ASCO, COGT presented promising primary results from the Ph3 PEAK study of bezuclastinib + sunitinib vs sunitinib in 2L GIST (slides here & PR here). Last week, COGT announced the FDA accepted their NDA in imatinib pretreated GIST under priority review (here); PDUFA date set for November 30, 2026.We model peak sales of ~$2.4B by 2035, inclusive of ~$1.5B of 2L GIST revenue, and make no change to our Buy rating and $45 TP. While we expect the initial launch http://www.streetinsider.com/Analyst+Comments/Cogent+%28COGT%29+Reiterated+at+Buy+by+Stifel+After+ASCO+Presentation+on+Bezuclastinib+/26579256.html Mon, 01 Jun 2026 07:31:40 -0400 COGT http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cogent+%28COGT%29/26578820.html <p>H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $55.00 price target on Cogent (NASDAQ: COGT).</p><p>The analyst commented: "At ASCO, Cogent presented the primary results from the Phase 3 PEAK trial, which evaluated bezuclastinib + Sutent (sunitinib) vs. Sutent in 2L, imatinib-resistant gastrointestinal stromal tumors (GIST). Treatment with bezuclastinib + Sutent (n=204) generated a statistically significant improvement compared to Sutent monotherapy in both ORR (45.6% vs 25.8%; p<0.0001) and PFS (16.5 months vs. 9.2 months [HR=0.50; 95% CI: 0.39-0.65; p<0.0001]), with a relatively consistent efficacy profile across genotype subgroups (see Figure 1 overleaf). The combination also reduced the risk http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Cogent+%28COGT%29/26578820.html Mon, 01 Jun 2026 06:57:55 -0400 COGT http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html <p>Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior progression-free survival compared to sunitinib alone in patients with gastrointestinal stromal tumors who previously received imatinib treatment.</p> <p>The trial met its primary endpoint with median progression-free survival of 16.5 months for the combination therapy versus 9.2 months for sunitinib monotherapy, representing a 50% reduction in risk of disease progression or death with a hazard ratio of 0.50. The objective response rate reached 46% for patients receiving the combination compared to 26% for those on sunitinib alone.</p> <p>The bezuclastinib combination showed efficacy across http://www.streetinsider.com/FDA/Cogent+Biosciences+reports+positive+Phase+3+trial+data+for+GIST+treatment/26577190.html Sat, 30 May 2026 08:00:17 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Press+Releases/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897 http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html <p align="center"><em>Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p&lt;0.0001) for bezuclastinib combination compared to sunitinib alone</em></p> <p align="center"><em>Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations </em></p> <p align="center"><em>Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination</em></p> <p align="center"><em>Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib</em></p> <p align="center"><em>Priority Review granted following FDA acceptance of http://www.streetinsider.com/Globe+Newswire/Cogent+Biosciences+Announces+Detailed+Clinical+Data+from+PEAK+Phase+3+Trial+with+Bezuclastinib+in+Combination+with+Sunitinib+in+Gastrointestinal+Stromal+Tumors+%28GIST%29+at+2026+American+Society+of+Clini/26577178.html Sat, 30 May 2026 08:00:00 -0400 A.20922990 A.35954321 A.50216726 COGT O.00048977 O.20737027 O.21612337 O.25157897